亚太地区糖类治疗市场预测至 2028 年 - COVID-19 影响和区域分析(按类别(分离和合成)、结构)[糖蛋白、针对唾液酸、蛋白聚糖、针对糖胺聚糖、糖基磷脂酰肌醇 (GPI) 锚定蛋白和肝素基聚糖、针对糖鞘脂和其他],适应症(血栓形成和化学预防、贫血、抗粘连和抗炎、白内障、戈谢病、MPS-1 和 IV、癌症、阿尔茨海默氏病、A 型和 B 型流感,以及其他),作用方式[抑制神经氨酸酶、抑制乙酰肝素酶和选择素并阻断生长因子和硫酸乙酰肝素之间的相互作用、促红细胞生成素和酶替代疗法 (ERT)、组织纤溶酶原激活剂、抑制葡萄糖神经酰胺合成白细胞介素 1 和 2 和 3、Beta 和 Gamma干扰素等]

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2028


No. of Pages: 210    |    Report Code: BMIRE00027511    |    Category: Life Sciences

Asia Pacific Glycomic Therapeutics Market

亚太地区的糖组治疗市场预计将从2022年的129.5082亿美元增长到2028年的345.9283亿美元;预计 2022 年至 2028 年复合年增长率为 17.8%。

糖组学在治疗学中的广泛应用为治疗提供利润丰厚的机会市场增长

Glycomics 是一种创造药物的新方法。它利用了聚糖作为改变生物系统中众多分子的主要手段的知识。这种改变为这些分子提供了完整的功能形式。大多数最畅销的生物制剂和一半的治疗蛋白(包括针对 COVID-19 的抗体)中都含有聚糖。这些蛋白质的聚糖经过定制,可以提高其有效性、降低所需剂量并减少负面影响。例如,了解聚糖的生物学功能使其成为治疗糖尿病、预防血液凝固和改善体外受精的药物的基本成分。微生物表面聚糖的变化通常与微生物对流行药物的耐药性有关。该特性用于检测感染样品中的特定聚糖,使感染细菌形成的保护性生物膜失效,并削弱微生物富含聚糖的细胞壁。超过 130 种不常见的遗传疾病,其中许多在儿童时期是致命的,都是由错误引起的。了解导致其中一些问题的聚糖有助于开发治疗方法。由于聚糖在研究细菌和病毒对人类免疫系统的攻击中发挥着至关重要的作用,因此它们被用于疫苗接种。此外,最近对引起 COVID-19 的 SARS-CoV-2 的研究表明,感染途径取决于病毒对人类聚糖的使用。糖组学有潜力为精准医学带来新的视角,目前精准医学由遗传和蛋白质组学工具主导。因此,糖组学在各个治疗领域的广泛采用将推动未来几年对这些技术的需求。尽管如此,治疗领域持续的研究和开发以及临床进步预计将在预测期内为糖组治疗市场创造利润丰厚的增长机会。

市场概览

亚太地区 (APAC) 是糖组疗法增长最快的市场。亚太地区糖组学治疗市场分为中国、日本、印度、韩国、澳大利亚和亚太其他地区。由于各国政府支持的改善、研究组织的合作、糖组研究机构的崛起以及医疗基础设施的进步,到 2022 年,亚太地区可能占全球糖组治疗市场约 11.89% 的份额。因此,该地区为糖组治疗市场参与者在预测期内提供了多种增长机会。

亚太地区糖组治疗市场收入和预测至 2028 年(十亿美元)

亚太地区糖组治疗市场细分

亚太地区糖组治疗市场根据类别、结构、适应症、作用方式和国家进行细分。

根据类别,亚太地区糖组治疗市场分为分离型和合成型。合成细分市场将在 2022 年获得更大的市场份额。根据结构,亚太糖组治疗市场分为糖蛋白、靶向唾液酸、蛋白聚糖、靶向糖胺聚糖、糖基磷脂酰肌醇 (GPI) 锚定蛋白和糖蛋白。基于肝素的聚糖,针对糖鞘脂等。到 2022 年,糖蛋白细分市场占据最大的市场份额。根据迹象,亚太糖组治疗市场分为血栓形成和治疗。化学预防、贫血、抗粘连和药物预防抗炎、白内障、戈谢氏病、MPS-1 和IV、癌症、阿尔茨海默病、甲型流感和流感乙等。甲型流感和甲型流感b细分市场在2022年占据最大的市场份额。根据作用方式,亚太地区糖组治疗市场分为抑制神经氨酸酶、抑制乙酰肝素酶和选择素以及阻断生长因子与硫酸乙酰肝素、促红细胞生成素和b之间的相互作用。酶替代疗法 (ERT)、组织纤溶酶原激活剂、抑制葡萄糖神经酰胺合酶、白细胞介素 1、2 和 3、β 和 3。 γ干扰素等。促红细胞生成素和酶替代疗法 (ERT) 细分市场在 2022 年占据最大的市场份额。按国家/地区划分,亚太地区糖组治疗市场分为中国、日本、印度、澳大利亚、韩国和亚太地区其他地区。 2022 年中国将主导市场。BioMarin Pharmaceutical Inc.; Genzyme 公司(赛诺菲);拜耳公司;阿尔泽恩公司;葛兰素史克公司;和 F. Hoffmann-La Roche Ltd. 是亚太地区糖组治疗市场的领先公司。



Asia Pacific Glycomic Therapeutics Strategic Insights

Strategic insights for Asia Pacific Glycomic Therapeutics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-glycomic-therapeutics-market-strategic-framework.webp
Get more information on this report

Asia Pacific Glycomic Therapeutics Report Scope

Report Attribute Details
Market size in 2022 US$ 12,950.82 Million
Market Size by 2028 US$ 34,592.83 Million
Global CAGR (2022 - 2028) 17.8%
Historical Data 2020-2021
Forecast period 2023-2028
Segments Covered By 类
  • 分离和合成
By 结构
  • 糖蛋白
  • 靶向唾液酸
  • 蛋白聚糖
  • 靶向糖胺聚糖
  • 糖基磷脂酰肌醇锚定蛋白和肝素基聚糖
  • 靶向糖鞘脂
By 适应症
  • 血栓形成及化学预防
  • 贫血
  • 抗粘连及抗炎
  • 白内障
  • 戈谢病
  • MPS-1 及 IV
  • 癌症
  • 阿尔茨海默病
  • 甲型及乙型流感
By 作用方式
  • 抑制神经氨酸酶
  • 抑制肝素酶和选择素并阻断生长因子与硫酸肝素
  • 促红细胞生成素和酶替代疗法
  • 组织型纤溶酶原激活剂之间的相互作用
  • 抑制葡萄糖神经酰胺合成酶
  • 白细胞介素 1
  • 2 和 3
  • β 和 γ 干扰素等
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • BioMarin Pharmaceutical Inc.
  • Genzyme Corporation (Sanofi)
  • Bayer AG
  • GlaxoSmithKline plc.
  • F.Hoffmann-La Roche Ltd
  • Get more information on this report

    Asia Pacific Glycomic Therapeutics Regional Insights

    The regional scope of Asia Pacific Glycomic Therapeutics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-glycomic-therapeutics-market-geography.webp
    Get more information on this report

    The List of Companies - Asia Pacific Glycomic Therapeutics Market

    1. BioMarin Pharmaceutical Inc.                    
    2. Genzyme Corporation (Sanofi)                 
    3. Bayer AG                                                            
    4. GlaxoSmithKline plc.         
    5. F. Hoffmann-La Roche Ltd           
    Frequently Asked Questions
    How big is the Asia Pacific Glycomic Therapeutics Market?

    The Asia Pacific Glycomic Therapeutics Market is valued at US$ 12,950.82 Million in 2022, it is projected to reach US$ 34,592.83 Million by 2028.

    What is the CAGR for Asia Pacific Glycomic Therapeutics Market by (2022 - 2028)?

    As per our report Asia Pacific Glycomic Therapeutics Market, the market size is valued at US$ 12,950.82 Million in 2022, projecting it to reach US$ 34,592.83 Million by 2028. This translates to a CAGR of approximately 17.8% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Glycomic Therapeutics Market report typically cover these key segments-

  • 类 (分离和合成)
  • 结构 (糖蛋白, 靶向唾液酸, 蛋白聚糖, 靶向糖胺聚糖, 糖基磷脂酰肌醇锚定蛋白和肝素基聚糖, 靶向糖鞘脂)
  • 适应症 (血栓形成及化学预防, 贫血, 抗粘连及抗炎, 白内障, 戈谢病, MPS-1 及 IV, 癌症, 阿尔茨海默病, 甲型及乙型流感)
  • What is the historic period, base year, and forecast period taken for Asia Pacific Glycomic Therapeutics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Glycomic Therapeutics Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2028
  • Who are the major players in Asia Pacific Glycomic Therapeutics Market?

    The Asia Pacific Glycomic Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • BioMarin Pharmaceutical Inc.
  • Genzyme Corporation (Sanofi)
  • Bayer AG
  • GlaxoSmithKline plc.
  • F.Hoffmann-La Roche Ltd
  • Who should buy this report?

    The Asia Pacific Glycomic Therapeutics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Glycomic Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.